A team from the University of Ottawa’s Faculty of Medicine has completed an exciting new study that reveals the inner workings of gene mutations that result in an ultra-rare syndrome with fewer than 100 reported cases since its first description in the early 1960s.
Alvotech resubmits its interchangeable Humira biosimilar as AbbVie clings to brand dominance
Billionaire Alvotech CEO Róbert Wessman told investors on Thursday that the company has resubmitted its Humira interchangeable biosimilar application to the FDA after receiving a
September 1, 2023